Inari Secures $45 Million Debt Financing to Bring Innovative Agriculture Technologies to Market
Inari, the biotechnology company developing next-generation seeds, announced that it has entered into a $45 million loan and security agreement with K2 HealthVentures (K2HV), a life sciences-focused investment firm.
The funds complement Inari’s recent $89 million equity raise and will be used to accelerate the development and commercialization of breakthrough gene-edited crops that address the challenges of climate change and improve productivity.
"Our alliance with K2HV enhances our financial position. It supports further expansion of our research and technology platform, as well as the development and commercialization of products that align sustainability with cutting-edge biotechnology,” said Ponsi Trivisvavet, chief executive officer of Inari. "The K2HV team has a strong understanding of our innovative approach to plant breeding and confidence in our vision of agriculture.”
Companion Medical Secures $27.5 Million Debt Financing from K2 HealthVentures
Companion Medical, Inc., an innovative diabetes company that developed the first and only FDA-cleared smart insulin pen and app system, today announced that it has entered into a loan and security agreement for up to $27.5 million with K2 HealthVentures (K2HV), a healthcare-focused specialty finance company.
"This financing enhances our financial flexibility as we continue to scale commercialization of our flagship product - InPen," said Sean Saint, chief executive officer of Companion Medical. "The K2HV team has a strong understanding of our innovative approach to diabetes management and the high-impact solution that InPen represents for people living with this disease. We are pleased to be able to partner with them on this transaction in support of our growth."